Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus by Roper, Rachel L.
Comparative evaluation of two severe acute
respiratory syndrome (SARS) vaccine candidates
in mice challenged with SARS coronavirus
Raymond H. See,1 Alexander N. Zakhartchouk,2 Martin Petric,1
David J. Lawrence,1 Catherine P. Y. Mok,1 Robert J. Hogan,33
Thomas Rowe,3 Lois A. Zitzow,34 Karuna P. Karunakaran,1 Mary M. Hitt,41
Frank L. Graham,4 Ludvik Prevec,4 James B. Mahony,4 Chetna Sharon,5
Thierry C. Auperin,5|| James M. Rini,5 Aubrey J. Tingle,6 David W. Scheifele,7
Danuta M. Skowronski,1 David M. Patrick,1 Thomas G. Voss,3"
Lorne A. Babiuk,2 Jack Gauldie,4 Rachel L. Roper,8 Robert C. Brunham1




1University of British Columbia Centre for Disease Control, Vancouver, BC V5Z 4R4, Canada
2Vaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon,
SK S7N 5E3, Canada
3Emerging Pathogens Department, Southern Research Institute, Birmingham, AL 35205, USA
4Departments of Pathology and Molecular Medicine and Biology, McMaster University,
Hamilton, ON L8N 3Z5, Canada
5Departments of Molecular and Medical Genetics and Microbiology and Biochemistry,
University of Toronto, Toronto, ON M5S 1A8, Canada
6Michael Smith Foundation for Health Research, Vancouver, BC V6H 3X8, Canada
7Vaccine Evaluation Centre, British Columbia Institute for Children’s and Women’s Health, BC
Children’s Hospital, Vancouver, BC V6H 3V4, Canada
8Brody School of Medicine, Department of Microbiology and Immunology, East Carolina
University, Greenville, NC 27834, USA
9Michael Smith Laboratories and Departments of Biochemistry and Molecular Biology and
Microbiology and Immunology, University of British Columbia, Vancouver, BC V6T 1Z3, Canada
Received 2 October 2005
Accepted 16 November 2005
Two different severe acute respiratory syndrome (SARS) vaccine strategies were evaluated for their
ability to protect against live SARS coronavirus (CoV) challenge in a murine model of infection.
A whole killed (inactivated by b-propiolactone) SARS-CoV vaccine and a combination of two
adenovirus-based vectors, one expressing the nucleocapsid (N) and the other expressing the spike
(S) protein (collectively designated Ad S/N), were evaluated for the induction of serum neutralizing
antibodies and cellular immune responses and their ability to protect against pulmonary SARS-CoV
replication. The whole killed virus (WKV) vaccine given subcutaneously to 129S6/SvEv mice
was more effective than the Ad S/N vaccine administered either intranasally or intramuscularly
in inhibiting SARS-CoV replication in the murine respiratory tract. This protective ability of the
WKV vaccine correlated with the induction of high serum neutralizing-antibody titres, but not with
cellular immune responses as measured by gamma interferon secretion by mouse splenocytes.
Titres of serum neutralizing antibodies induced by the Ad S/N vaccine administered intranasally
or intramuscularly were significantly lower than those induced by the WKV vaccine. However,
Ad S/N administered intranasally, but not intramuscularly, significantly limited SARS-CoV
replication in the lungs. Among the vaccine groups, SARS-CoV-specific IgA was found only in the
sera of mice immunized intranasally with Ad S/N, suggesting that mucosal immunity may play a
role in protection for the intranasal Ad S/N delivery system. Finally, the sera of vaccinated mice
contained antibodies to S, further suggesting a role for this protein in conferring protective immunity
against SARS-CoV infection.
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INTRODUCTION
Severe acute respiratory syndrome (SARS) emerged as a new
disease threat in late 2002 and spread to several countries
with considerable loss of life (8096 cases, 774 deaths; http://
www.who.int/csr/sars/country/table2004_04/_21/en/index.
html). The aetiological agent of SARS is a new human coro-
navirus (CoV) identified by its unique genome sequence
(Marra et al., 2003; Rota et al., 2003) and by experimental
infection of macaques to fulfil Koch’s postulates (Fouchier
et al., 2003).
Currently, there is no effective treatment for SARS. Preven-
tion through contact-reduction or transmission-blocking
measures has been the only means available to modify the
devastating impact of this illness. Prevention through
vaccination would be an attractive alternative that is less
reliant on individual case detection to be effective. No
vaccines are currently licensed for any of the human CoVs,
but effective vaccines have been produced for some animal
CoVs, such as certain strains of Infectious bronchitis virus
(poultry), Bovine coronavirus and Canine coronavirus
(Cavanagh, 2003; Enjuanes et al., 1995; Pratelli et al., 2003;
Saif, 2004; Takamura et al., 2002). Individuals convalescing
from SARS develop high titres of neutralizing antibodies
(Tan et al., 2004) and the appearance of antibodies coincides
with the onset of resolution of SARS pneumonia (Liu et al.,
2004; Woo et al., 2004). Thus, there is some optimism that
an effective vaccine against SARS-CoV may also be possible.
Coronavirus spike (S) proteins have long been known to be a
major determinant in coronavirus pathogenesis, given that
this viral protein interacts with cellular receptors as well as
contains determinants for eliciting a protective immune
response (Enjuanes et al., 1995; Navas-Martin & Weiss,
2003). Consequently, the SARS-CoV S glycoprotein, shown
to be responsible for receptor binding to the cellular
angiotensin-converting enzyme 2 (ACE2), is an attractive
target for both vaccine and therapeutics development (Li
et al., 2003). This is strongly supported by the finding that
a human mAb that binds to the N terminus of the S pro-
tein potently neutralizes SARS-CoV infection and inhibits
syncytia formation through blocking of receptor binding
(Berger et al., 2004).Moreover, the S protein has been shown
to induce serum neutralizing antibodies and to confer pro-
tective immunity against SARS-CoV challenge in mice and
African green monkeys (Bisht et al., 2004; Bukreyev et al.,
2004; Yang et al., 2004). Studies from other animal CoV
vaccines have also shown that the CoV nucleocapsid (N)
protein, which encapsidates the viral genome, may represent
another antigen candidate for vaccine development (Antón
et al., 1996; Olsen, 1993). Although antibodies to CoV N
proteins have no virus-neutralizing activity in vitro, there is
evidence that the protein may provide in vivo protection by
induction of cell-mediated immunity (Enjuanes et al., 1995;
Stohlman et al., 1995; Wesseling et al., 1993). The N protein
has been shown to generate CoV-specific CD8+ T cells
(Boots et al., 1991; Seo et al., 1997; Stohlman et al., 1993,
1995) and to provide protection in animals following
infection (Collisson et al., 2000; Seo et al., 1997).
Several potential strategies can be considered for vaccination
against SARS-CoV, including a whole killed virus (WKV)
vaccine, a live-attenuated SARS-CoV vaccine, a viral vector
such as adenovirus or Vaccinia virus expressing SARS-CoV
genes, recombinant SARS-CoV proteins and DNA-based
vaccines (reviewed by See et al., 2005). In this report, two
SARS vaccine approaches were developed in parallel and
evaluated for their efficacy in a murine SARS model by the
SARS Accelerated Vaccine Initiative described elsewhere
(Finlay et al., 2004). We report the first direct comparison of
a whole killed SARS-CoV vaccine and a combination of
attenuated adenoviruses, one expressing SARS-CoV S pro-
tein and the other expressing the N protein (collectively
called Ad S/N), for their ability to protect against live SARS-
CoV challenge in vivo. Vaccine candidates were developed
in parallel and evaluated for immunogenicity and efficacy
against SARS-CoV infection in a murine model previously
demonstrated to support virus replication (Hogan et al.,
2004).
METHODS
WKV vaccine. The Toronto-2 (Tor2) SARS-CoV strain (Marra
et al., 2003) was kindly provided by Dr Tim Booth, Canadian
Science Centre for Human and Animal Health, Winnipeg, Canada
(Public Health Agency of Canada). SARS-CoV Tor2 strain was
passaged in Vero E6 cells, purified by ultracentrifugation and sub-
sequently inactivated with b-propiolactone (BPL) in a biosafety-level
3 facility, as described previously (Zakhartchouk et al., 2005a).
Inactivated virus was stored at 280 uC until use. BPL-inactivated
virus (approx. 1 mg ml21 by Coomassie blue dye assay) was diluted
in 0?1 M PBS, pH 7?0 (without divalent cations), to a protein con-
centration of 250 mg ml21. For animals receiving inactivated virus in
alum adjuvant (2% Alhydrogel; Accurate Chemical & Scientific
Corp.), BPL-inactivated virus (500 mg ml21) was diluted in PBS and
mixed with 2% Alhydrogel diluted 1 : 4 for ¢6 h at 4 uC to give a
final concentration of 250 mg virus and 2?5 mg Alhydrogel ml21.
Adenovirus-vectored SARS vaccine. The full-length SARS-CoV
N gene (nt 28120–29482 of the SARS-CoV genome, GenBank acces-
sion no. NC_004718; Marra et al., 2003) was amplified from an iso-
late of the Tor2 strain by RT-PCR and inserted into the pCR-Blunt
II-TOPO vector (Invitrogen) to generate pTOPO-N. The N gene
fragment was then isolated from pTOPO-N and inserted into the
Ad5 shuttle plasmid pDC516(io) (AdMax Hi-IQ kit J; Microbix)
downstream of a modified murine cytomegalovirus immediate-early
promoter and upstream of the simian virus 40 polyadenylation signal.
The S gene (corresponding to nt 21492–25259 of the SARS-CoV
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genome) was PCR-amplified from the plasmid pIR-GP SARS-V5,
obtained from Nabil Seidah (Institut de Recherches Cliniques
de Montreal, Quebec, Canada) and inserted into pDC516(io) to
generate the shuttle plasmid pDC516(io)SARS-S. 293-IQ cells
(Microbix) (Matthews et al., 1999) were co-transfected with the
genomic plasmid pBHGfrtdE1,3FLP (Ng et al., 2000) and the shuttle
plasmid pDC516(io)SARS-N or pDC516(io)SARS-S to generate
AdSARS-N complete (shortened to Ad N) and AdSARS-S (shortened
to Ad S), respectively, by Flp recombinase-mediated site-specific
recombination. These vectors were amplified, purified and titrated by
plaque assay as described by Hitt et al. (2005) with no evidence of
heterologous insert instability. The Ad N vector described here car-
ried the same N gene as Ad5-N-V reported recently (Zakhartchouk
et al., 2005b), but differed in the promoter (modified murine cyto-
megalovirus promoter in this Ad N construct) used in controlling N
gene transcription. Expression of the SARS-CoV N or S protein was
confirmed by Western blot analysis of lysates from human embryo-
nic kidney (HEK293) or HeLa cells infected with the adenovirus-
based vector for 24 h, using convalescent sera from SARS patients as
a source of antibodies.
Molecular cloning, expression and purification of SARS-CoV
N protein in Escherichia coli. DNA fragments containing the
SARS-CoV N gene were generated by RT-PCR using SARS-CoV
genomic RNA as the template. In order to subclone the PCR
product as an NdeI–EagI fragment into the pET30b(+) vector
(Novagen), the following forward and reverse primers were used: 59-
GAATTCCATATGTCTGATAATGGACCCAATC-39 and 59-GAAA-
GCCGGCCGATGCCTGAGTTGAATCAGCAG-39. The PCR mixture
contained 2 mM MgSO4, 200 mM dNTPs, 2?5 U Pfu DNA polymer-
ase and 25 pmol each oligonucleotide primer. PCR cycling condi-
tions were as follows: one cycle of 95 uC for 2 min, followed by 35
cycles of 94 uC for 15 s, 58 uC for 30 s and 72 uC for 2 min. Plasmids
containing the N gene were then transformed into E. coli strain
BL21 (DE3). SARS-CoV N protein expression was induced in trans-
formed BL21 (DE3) host cells by adding 1 mM IPTG for 4 h. The
expressed N protein, containing an N-terminal histidine tag, was
subsequently purified by using the His Bind purification system
(Novagen) and confirmed by SDS-PAGE.
S protein fragment (aa 318–510). A mammalian expression
vector consisting of a codon-optimized gene encoding the SARS-
CoV S protein aa 318–510 fragment (kindly provided by David
Kelvin, University of Toronto, Canada) downstream of the mam-
malian transin-secretion signal peptide, a protein A purification tag
(Sanchez-Lopez et al., 1988), and a tobacco etch virus (TEV) pro-
tease-cleavage site was generated by using the pIRESpuro3 plasmid
(Clontech). The secreted N-terminal fusion protein was purified
from the culture medium of stably transformed HEK293T cells by
IgG affinity chromatography. Following TEV cleavage, the S protein
was further purified by hydrophobic-interaction chromatography,
cation-exchange chromatography and gel filtration. Purity was
assessed by Coomassie blue staining following SDS-PAGE.
Mice. Six-week-old female 129S6/SvEv mice, free of adventitious
rodent pathogens, ectoparasites and endoparasites, were purchased
from Taconic Farms (Germantown, NY, USA). Mice were housed in
groups of eight in polysulfone microisolator cages on Sani-Chip
bedding (PJ Murphy Forest Products). They were provided with
food and water ad libitum. All procedures were in accordance with
the NRC (1996), the Animal Welfare Act and the CDC NIH (1999).
Mice immunizations. Two groups of 129S6/SvEv mice were used
in this study. Group 1 mice (n=5 per vaccine group) were immu-
nized on day 0 and week 4 prior to sacrifice at week 7. These mice
were examined for both humoral and cell-mediated immune
responses as a result of immunization with the different SARS vac-
cines. Group 2 mice (n=8 per vaccine group) were immunized as
above, but were subsequently challenged with live SARS-CoV Tor2
at week 7 (see below). For immunizations on day 0, mice were
vaccinated either with a combination of adenoviruses, one express-
ing SARS-CoV S protein and the other expressing SARS-CoV N pro-
tein (collectively called Ad S/N), or with the WKV vaccine in the
presence or absence of alum. Specifically, 129S6/SvEv mice were
immunized in one the following manners: (i) subcutaneously with
0?2 ml 0?1 M PBS, pH 7?0 (without divalent ions); (ii) subcuta-
neously with WKV alone, consisting of 50 mg inactivated virus in
0?2 ml 0?1 M PBS; (iii) subcutaneously with WKV vaccine plus
alum, consisting of 50 mg inactivated virus plus 500 mg Alhydrogel
in 0?2 ml 0?1 M PBS; (iv) intranasally with adenovirus-based SARS-
CoV S and N vectors (36108 p.f.u. each) in a total volume of 30 ml
(Ad S/N IN); (v) intramuscularly with adenovirus-based SARS-CoV
S and N vectors (36108 p.f.u. each) into the hind leg (Ad S/N IM);
(vi) intranasally or intramuscularly with a control adenovirus 5
(66108 p.f.u.) that lacks SARS-CoV genes (Ad-Ctrl). Before intra-
nasal vaccination with the recombinant adenovirus SARS vaccines,
each mouse was anaesthetized with isoflurane. Four weeks after the
initial immunization, mice were reimmunized with the same vaccine
at the same dose and monitored until week 7.
SARS-CoV challenge studies. Following vaccination at 0 and
4 weeks, group 2 mice were challenged at 7 weeks with the SARS-
CoV Tor2 strain. For challenge experiments, eight mice from each
vaccine group were anaesthetized with isoflurane and infected via
intranasal inhalation with 16106 p.f.u. SARS-CoV Tor2 in a total
volume of 30 ml. On day 3 post-challenge, half (n=4) of the animals
were euthanized with CO2 and necropsied. The remaining four ani-
mals were sacrificed in the same way on day 7 post-challenge.
Collection of blood and lung tissues. Blood was collected from
each mouse via retro-orbital puncture during the following time
periods: prior to the first immunization, week 4 (pre-boost) and
week 7 (pre-challenge). Blood samples were processed by clotting
for 30 min at room temperature and centrifuged to remove cellular
debris, and the resulting sera were stored at 280 uC. The lungs from
each mouse were removed aseptically and homogenized in PBS as
described below. Fifty microlitres of the lung homogenate was
mixed with 450 ml TRIzol reagent and stored at 280 uC for RNA
analysis. The remaining lung homogenate was stored at 280 uC for
virus titration.
Virus titration. Frozen lung (previously unwashed) samples were
homogenized in PBS containing penicillin (100 U ml21), strepto-
mycin (100 mg ml21) and gentamicin (50 mg ml21). Lung homoge-
nates were then diluted serially (half-log) in Dulbecco’s minimal
essential medium containing 2% heat-inactivated fetal bovine serum
(Atlanta Biologicals) and antibiotics (penicillin and streptomycin)
before addition to 90–95% confluent Vero E6 monolayers in 96-well
plates. Cells were monitored for cytopathic effect (CPE) in positive-
control wells. After incubation for 48 h at 37 uC, 5% CO2, CPE was
measured by the addition of neutral red to the wells and measure-
ment of A540. TCID50 was determined by a 50% reduction in CPE
as described previously (Guo et al., 2004; Schmidt, 1989; Smee et al.,
2001). Viral titres were expressed as log10 TCID50 ml
21 for lung
homogenates.
Virus neutralization assay. Twofold dilutions of heat-inactivated
serum were tested for the presence of antibodies that would neutra-
lize the infectivity of 100 TCID50 of SARS-CoV in Vero E6 cell
monolayers as described previously (Zakhartchouk et al., 2005a).
The CPE of SARS-CoV on Vero E6 cell monolayers was read on day 3.
The dilution of serum that completely inhibited CPE in 50% of the
wells was calculated as described previously (Reed & Muench, 1938).
Gamma interferon (IFN-c) ELISPOT assay. MultiScreen-IP
(Millipore) 96-well plates were coated overnight with rat anti-mouse
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IFN-c (Pharmingen) at 4 uC. Plates were washed with sterile PBS
and incubated in triplicate with 26105 murine splenocytes per well
in RPMI 1640. Recombinant N protein was isolated as described
above and added to a final concentration of 10 mg ml21. After incu-
bation for 40 h at 37 uC, plates were washed six times with PBS
containing 0?05% Tween 20 and incubated overnight with 100 ml
biotinylated rat anti-mouse IFN-c (Pharmingen) per well. After
washing, streptavidin–alkaline phosphatase was added and the plates
were developed and read as described previously (Zakhartchouk
et al., 2005a).
Western blot analysis using pooled mice sera. Purified bac-
terial N protein (0?2 mg) and either 0?5 or 5 mg truncated mamma-
lian S protein (aa 318–510) were prepared in SDS sample buffer,
separated by SDS-PAGE and transferred onto a nitrocellulose mem-
brane. Specific proteins on the membranes were visualized as
described previously (Zakhartchouk et al., 2005a).
SARS-CoV-specific ELISA. Total SARS-CoV-specific IgG, IgG
isotypes and IgA titres in sera from immunized mice were measured
by ELISA. Each well of a 96-well plate was coated overnight
with 0?1 ml purified inactivated SARS-CoV at a concentration of
1 mg ml21. Washing of plates, addition of sera and colour develop-
ment were performed as described previously (Zakhartchouk et al.,
2005a).
RT-PCR assay for SARS-CoV RNA. Fifty microlitres of lung
homogenate was placed in TRIzol reagent and processed as des-
cribed previously (Hogan et al., 2004). RNA was isolated with an
RNeasy kit (Qiagen) and tissue RNA was quantified with RiboGreen
(Molecular Probes). DNase treatment was performed to eliminate
the remaining DNA in the RNA samples. The SARS-CoV genome
was detected with LUX primer sets for the SARS-CoV N domain
and the Superscript III Platinum One-step Quantitative RT-PCR
System (Invitrogen) in a LightCycler (Roche) as described previously
(Hogan et al., 2004). To confirm the RT-PCR results, RT-PCR pro-
ducts from some of the study samples were verified by gel electro-
phoresis. The results ranged from less than one copy to up to 10 000
copies per reaction.
Statistical analyses. Statistical significance was assessed by using
the non-parametric Wilcoxon rank sum test (Hollander & Wolfe,
1973). Differences between mean values for the vaccine groups were
considered significant if the P value (two-tailed) was ¡0?05.
RESULTS
Neutralizing-antibody responses to SARS
vaccines
In contrast to the PBS control, group 1 mice vaccinated
with the WKV vaccine demonstrated detectable serum
neutralizing-antibody titres at 4 weeks, and by 7 weeks the
titres had increased 40-fold (Fig. 1a). The addition of alum
to the WKV vaccine preparation did not increase serum
neutralizing-antibody levels significantly at either time
period (Fig. 1a). Mice given Ad S/N IM showed similar
serum neutralizing-antibody titres at weeks 4 and 7, but
overall titres were 25-fold lower than those observed in the
sera of mice given WKV with or without alum (Fig. 1a). In
contrast, the neutralizing-antibody titres in the sera of Ad
S/N IN-vaccinated mice were low during the first 4 weeks,
but increased 11-fold at the end of 7 weeks, albeit with
overall titres that were lower than those found in Ad S/N IM
sera (Fig. 1a). No serum neutralizing-antibody responses
could be detected within the 7 week period in mice
immunized with the control adenovirus (Ad-Ctrl) (Fig. 1a).
Total SARS-CoV-specific IgG titres in sera from weeks 4
and 7 were determined by ELISA using inactivated SARS-
CoV as the capture antigen. As shown in Fig. 1(b), no
significant difference in total SARS-CoV-specific IgG levels
was observed between WKV alone and WKV plus alum at
either week 4 or week 7, supporting the data in Fig. 1(a).
However, a 19-fold difference (P=0?02) in total SARS-
CoV-specific IgG levels was observed at weeks 4 and 7 in the
sera of mice vaccinated with WKV alone or with WKV plus
alum (Fig. 1b). The total SARS-CoV-specific IgG levels
measured from week 7 sera of either Ad S/N IM- or Ad S/N
IN-vaccinated mice did not differ statistically from those of
week 4 sera and were approximately sevenfold lower than
those induced by the WKV plus alum vaccine at week 7
(Fig. 1b). No SARS-CoV-specific IgG was detected in the
sera of mice vaccinated with either PBS or Ad-Ctrl at either
time period. The SARS-CoV-specific IgG subclasses were
also determined in week 7 sera. Fig. 1(c) shows that SARS-
CoV-specific IgG2a levels in week 7 sera were significantly
higher than IgG1 levels in response to WKV alone (P=
0?008), WKV plus alum (P=0?03) or Ad S/N given either
intramuscularly (P=0?002) or intranasally (P=0?0001).
The addition of alum to WKV significantly augmented
(P=0?008) the SARS-CoV-specific IgG1, but not the IgG2a,
response (Fig. 1c). Our results showed that the WKV alone
and Ad S/N IM vaccines induced similar levels of SARS-
CoV-specific IgG isotypes at week 7. Additionally, we analy-
sed the sera of all vaccinated mice by ELISA for the presence
of SARS-CoV-specific IgA, which would indicate vaccine
stimulation of mucosal immunity. The results in Fig. 1(d)
indicated that sera from mice vaccinated with Ad S/N IN
showed a greater than 3 log increase in SARS-CoV-specific
IgA titres compared with Ad-Ctrl-vaccinated mice at weeks
4 and 7. No detectable SARS-CoV-specific IgA was found in
the sera of mice immunized with either WKV (with or
without alum) or Ad S/N IM for up to 7 weeks (Fig. 1d).
To determine the SARS-CoV proteins recognized by the sera
of mice vaccinated with either WKV or Ad S/N at week 7,
Western blot analysis was performed on purified recombi-
nant S or N proteins. In contrast to mice receiving either
PBS or Ad-Ctrl, bands corresponding to the molecular
masses of the S fragment (Fig. 2a) and the N protein
(Fig. 2b) were detected by pooled sera from mice vacci-
nated with WKV, WKV plus alum, Ad S/N IM or Ad S/N
IN. Interestingly, a consistently stronger immunoreactivity
towards both the S and N proteins was evident in the sera of
mice vaccinated with WKV plus alum compared with WKV
alone (Fig. 2a and b, lanes 2 and 3), suggesting that alum
may either enhance the response of this class of antibody or
increase its avidity. In addition, the immunoreactivity of
sera from Ad S/N IM- or Ad S/N IN-vaccinated mice to
recombinant S protein was much weaker than that observed
with WKV sera and required 10-fold more antigen to
visualize the immunoreactive S protein band (Fig. 2a).
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Collectively, our results indicate that the S and N proteins in
the WKV and Ad S/N preparations were able to induce a
readily quantifiable humoral response.
Cell-mediated immune responses to WKV and
Ad S/N
The types of immune response elicited by WKV or Ad S/N
after initial immunization and boost were evaluated further
by measuring the secretion of IFN-c by mouse splenocytes
stimulated in vitro with recombinant SARS-CoV N protein.
Fig. 3 shows that, when stimulated with N protein, spleno-
cytes from mice vaccinated with either WKV or Ad S/N
secreted significantly higher levels (P=0?002) of IFN-c
compared with splenocytes from control mice. As indicated
in Fig. 3, vaccination of mice with Ad S/N IM resulted in the
highest number of IFN-c-secreting splenocytes, followed by
WKV alone, Ad S/N IN and WKV plus alum, in descending
order.
Reduction of lung viral load in mice immunized
with the Ad S/N or WKV vaccine
We assessed the efficacy of two SARS vaccines by using the
129S6/SvEv mouse model as described previously (Hogan
et al., 2004). From the vaccination period to the time of
SARS-CoV challenge, mice appeared normal in activity and
appetite and showed no signs of adverse reaction to any of
the vaccines at the administration site. Viral titres were
assessed in lung homogenates during the early and late
courses of infection by using a CPE assay. Pilot studies with
PBS showed that SARS-CoV titres in the murine respiratory
tract were highest at day 3 post-challenge and dropped
dramatically to undetectable levels by day 7 post-challenge
(Hogan et al., 2004). SARS-CoV replication in the lungs was
assessed in the group 2 mice by examining viral titres and
RNA levels in lung homogenates. Fig. 4(a) shows that lung
viral titres in mice immunized with WKV in the absence or
presence of alum were reduced by 4 logs to undetectable
levels compared with titres observed in the PBS control on
Fig. 1. Immunogenicity responses of group 1 mice to SARS vaccines. (a) Neutralizing-antibody titres (mean±SD for five
mice) of week 4 (empty bars) and 7 (filled bars) sera from mice vaccinated as indicated. (b) Total SARS-CoV-specific IgG
titres (mean±SD for five mice) are shown for week 4 (empty bars) and 7 (filled bars) sera of controls and vaccinated mice.
(c) Titres of SARS-CoV-specific IgG1 (empty bars) and IgG2a (filled bars) subclasses (mean±SD for five mice) in the sera of
control and vaccinated mice 7 weeks after first immunization. (d) SARS-CoV-specific IgA titres in week 4 (empty bars) and 7
(filled bars) sera of mice vaccinated as indicated.
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day 3 post-challenge (P=0?02). Lung viral titres in animals
vaccinated with Ad S/N IN were also reduced significantly
(P=0?03) compared with Ad-Ctrl-vaccinated animals
harvested on day 3, albeit not as strongly as observed with
WKV (Fig. 4a). A similar reduction trend, although not
statistically significant, was observed when the lung viral
titres of Ad S/N IM-vaccinated mice were compared with
those of mice vaccinated with Ad-Ctrl (Fig. 4a). Viral titres
in lung homogenates were below the assay detection limit
for all vaccine groups on day 7 post-challenge. Levels of
SARS-CoV RNA correlated well with the lung viral-titre
data on day 3 post-challenge. Compared with the PBS
control on day 3 post-challenge, levels of viral RNA were
undetectable in lung homogenates of mice immunized with
WKV alone or with WKV plus alum (Fig. 4b). A significant
reduction (P=0?02) in the level of SARS-CoV RNAwas also
observed in day 3 post-challenge lung homogenates of mice
given Ad S/N IN compared with animals vaccinated with
Ad-Ctrl. SARS-CoV RNA was still detectable in lung homo-
genates at day 7 post-challenge for mice vaccinated with
either PBS or Ad-Ctrl (Fig. 4b). By day 7 post-challenge,
SARS-CoV RNAwas undetectable for both groups ofWKV-
vaccinated animals (Fig. 4b). Residual low levels of SARS-
CoV RNA were observed at day 7 post-challenge for mice
immunized with Ad S/N IN or Ad S/N IM, but the levels
were not significantly different from those of Ad-Ctrl-
vaccinated mice (Fig. 4b).
DISCUSSION
We have described the first direct comparison of two SARS
vaccines, WKV and Ad S/N, an adenovirus-based vaccine
consisting of SARS-CoV S andNproteins. Induction of serum
neutralizing antibodies and cellular immune responses was
evaluated in order to define correlates of immunity for
protection against SARS-CoV replication in lung tissue. Our
findings showed that vaccinationwithWKV inmice induced
much higher levels of serum neutralizing antibodies than Ad
S/N given intramuscularly or intranasally. The addition of
alum to the WKV vaccine preparation did not increase the
serum virus-neutralizing activity significantly. In contrast,
Ad S/N IM induced the highest cellular immune response
among the tested vaccines, as measured by IFN-c secretion
by splenocytes of vaccinated mice following in vitro stimu-
lation with recombinant N protein. The number of IFN-c-
secreting splenocytes in Ad S/N IM-immunized mice was
significantly higher (1?5–2?5-fold) than those of mice vacci-
nated with Ad S/N IN, WKV alone or WKV plus alum.
However, when evaluating protection against pulmonary
virus replication in 129S6/SvEv mice, the WKV vaccine was
more effective than Ad S/N administered intramuscularly or
intranasally in reducing pulmonary SARS-CoV replication
following challenge. No significant protection was observed
in mice vaccinated with Ad S/N IM compared with the
control animals. Our results suggest that humoral immu-
nity, but not cellular immune responses, correlates well with
the ability of WKV to protect against pulmonary SARS-CoV
replication.
Recipients of the Ad S/N IN vaccine also demonstrated
significantly reduced levels of SARS-CoV replication in the
Fig. 2. Western blot analysis of week 7 sera from group 1 mice
vaccinated as indicated and probed against the following anti-
gens: (a) purified recombinant SARS-CoV S protein fragment (aa
318–510) (lanes 1–3, 0?5 mg protein; lanes 4–6, 5 mg protein);
(b) recombinant His-tagged N protein (0?2 mg in each lane).
Arrows indicate the position of the S and N proteins.
Fig. 3. Cellular immune responses of group 1 mice to SARS
vaccines. The number of IFN-c-secreting splenocytes per 106
cells from mice harvested 7 weeks after vaccination and stimu-
lated in vitro with recombinant N protein for 24 h is shown.
Results represent the mean±SD (for triplicate wells) for groups
of five mice.
646 Journal of General Virology 87
R. H. See and others
lungs, although protection was not as effective as the WKV
vaccine. In contrast, the intramuscular route of the Ad S/N
vaccine had only a limited effect in reducing pulmonary
SARS-CoV replication, despite demonstrating high serum
neutralizing-antibody titres prior to SARS-CoV challenge
and the ability to induce a robust cellular immune response.
In our study, the two intramuscular injections of the Ad
S/N vaccine produced a strong SARS-CoV-specific IgG1 and
IgG2a antibody response in mice, with IgG2a titres signifi-
cantly higher than IgG1. The serum neutralizing-antibody
levels in Ad S/N IN-vaccinated mice were lower than in
animals immunized with Ad S/N IM. This result suggests
that other factors, such as mucosal immunity (e.g. secretory
IgA and/or mucosal T cells), may play an important role in
limiting lung virus replication by the Ad S/N IN vaccine. The
detection of serum SARS-CoV-specific IgA in mice vacci-
nated with Ad S/N IN, but not with Ad S/N IM or Ad-Ctrl,
suggests that mucosal SARS-CoV-specific IgA does play an
important role in conferring protection against SARS-CoV
pulmonary replication. Moreover, the IFN-c-secreting
response observed in splenocytes of Ad S/N IN-vaccinated
mice was more than twofold lower than that found in mice
immunizedwithAd S/N IM, indicating that cellular immune
responses do not contribute to protection against SARS-
CoV challenge as strongly as an antibody response, con-
sistent with other studies (Yang et al., 2004). Our result
points to a potential approach whereby SARS-CoV infection
could potentially be blocked at the primary site of entry (e.g.
respiratory tract) by using an intranasal adenovirus-based
vaccine (Bukreyev et al., 2004; Peiris et al., 2003).
There are several possible explanations as to why the WKV
vaccine conferred more protection against pulmonary
SARS-CoV replication than the Ad S/N vaccine. Firstly,
the WKV vaccine induced higher serum virus-neutralizing
activity than mice immunized with either Ad S/N IN or Ad
S/N IM. Secondly, the route of administration (subcuta-
neous for WKV vaccine, intranasal or intramuscular for Ad
S/N) or the vaccine dose may contribute to the protective
differences observed between theWKV andAd S/N vaccines.
Thirdly, expression of the S protein from the Ad S/N con-
struct may be lower than that of WKV. This was evident in
Fig. 2(a), where sera from WKV-vaccinated mice showed a
much stronger immunoreactivity towards the S protein than
sera from Ad S/N-immunized animals. Indeed, we have
recently constructed a single adenovirus vector containing
codon-optimized S and N genes and found that the serum
neutralizing-antibody titres induced by this construct, when
given intranasally/intramuscularly to mice, were compar-
able to levels found in animals vaccinated with WKV (data
not shown). Lastly, unlike the Ad S/N vaccine, which con-
tains only genes that encode the N and S proteins, the WKV
vaccine contains the complete complement of viral proteins
present in the natural virion conformation and thus may
induce a broader immune response. In support of this,
others have reported that sera from mice vaccinated with
inactivated SARS-CoV contain antibodies to a number of
proteins including S, N, M and 3CL of the SARS-CoV Tor2
strain (Xiong et al., 2004).
Several groups have developed SARS vaccines based on
the SARS-CoV S protein as a target. A DNA-based vaccine
(Buchholz et al., 2004), a modified Ankara vaccinia virus
(Bisht et al., 2004) and a recombinant attenuated parain-
fluenza virus (Bukreyev et al., 2004) containing the SARS-
CoV S gene have been shown to induce serum neutralizing
antibodies and to inhibit pulmonary virus replication in
animals. These animal models for SARS include macaques
Fig. 4. Protection of group 2 mice from pulmonary SARS-CoV replication after immunization with SARS vaccines. (a) Viral
titres (mean±SD for four mice) were determined in homogenates of lungs harvested from vaccinated mice after challenge with
SARS-CoV for the indicated number of days. The lower limit of virus detection was 1?0 log10 TCID50 ml
”1. (b) SARS-CoV
genome copy number (mean±SD for four mice) was determined in homogenates of lungs from vaccinated mice challenged for
the indicated number of days.
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(Fouchier et al., 2003; Kuiken et al., 2003), African green
monkeys (Bukreyev et al., 2004; McAuliffe et al., 2004),
ferrets (Martina et al., 2003), mice (Glass et al., 2004;
Subbarao et al., 2004) and hamsters (Roberts et al., 2005).
Although all of the above animal models support virus
replication, no single animal species has been shown to
reproduce all of the clinical signs and lethality observed in
humans infected with SARS-CoV. The importance of a
humoral response to the S protein has been demonstrated by
the protection of naı̈ve mice from live SARS-CoV challenge
after passive IgG transfer from immunized animals (Yang
et al., 2004). In contrast, antiserum to N protein has not
been shown to contain neutralizing antibodies (Pang et al.,
2004). However, the N protein has been shown to be a
vaccine candidate by inducing SARS-CoV antigen-specific
T-cell and virus-neutralizing responses (Kim et al., 2004;
Zhu et al., 2004). Several laboratories (He et al., 2004; Qu
et al., 2005; Takasuka et al., 2004; Tang et al., 2004) have
developed an inactivated whole SARS-CoV vaccine that
can induce serum neutralizing antibodies when injected
into mice, but whether these vaccines can confer protective
immunity against live SARS-CoV challenge was not
reported. Recently, a WKV vaccine has been shown to pro-
tect against pulmonary SARS-CoV replication in BALB/c
mice, although characterization of the immune response
was not reported (Stadler et al., 2005). In this study, we
also demonstrated that a whole killed SARS-CoV vaccine
can induce serum neutralizing antibodies and can protect
against SARS-CoV challenge in mice. We showed that
protection from SARS-CoV infection by theWKV vaccine is
associated with the induction of both an IgG1 and IgG2a
immune response. The addition of alum, which selectively
stimulates IgG1 immune responses (Kenney & Edelman,
2003), only increased serum SARS-CoV-specific IgG1 but
not IgG2a responses, which is consistent with the findings
of others (Takasuka et al., 2004). In our study, total serum
SARS-CoV-specific IgG and neutralizing-antibody levels
were not enhanced by the addition of alum to the WKV
vaccine preparation and protection from virus replication
was not improved discernibly. In contrast, the immuno-
reactivity of pooled mouse sera towards both the full-length
N protein and the S protein fragment was enhanced when
theWKV vaccine formulation contained alum. These results
suggest that the inclusion of alum in the WKV vaccine
may lead to enhanced production of antibody to denatured
protein. Interestingly, the S protein domain (aa 318–510)
recognized by the sera of WKV-vaccinated mice in our
studies is known to bind to the SARS-CoV functional
receptor, ACE2 (Babcock et al., 2004; Wong et al., 2004;
Xiao et al., 2003). Antibodies present against this S domain
may explain why sera from our WKV-vaccinated mice were
able to block SARS-CoV-mediated CPE in Vero E6 cells.
In summary, this is the first description of two SARS
vaccines evaluated head-to-head for their ability to induce
immunogenicity and to reduce viral load in the murine
respiratory tract. Our results showed that the WKV vaccine
was more effective than the Ad S/N vaccine in the reduction
of viral load in the respiratory tract of vaccinated mice after
live SARS-CoV challenge, with the intranasal route of Ad
S/N also providing significant protection. Such a direct
comparison of SARS vaccines in an animal model will not
only determine which vaccine strategy is more effective, but
will also shorten the time lines for moving the best candidate
forward into human testing.
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